{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:01Z","timestamp":1791357241676,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001470","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T00:00:00Z","timestamp":1402358400000}}],"reference-count":207,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001470.pub2","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T12:59:32Z","timestamp":1402405172000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders"],"prefix":"10.1002","volume":"2014","author":[{"given":"Jataveda","family":"Mahapatra","sequence":"first","affiliation":[{"name":"Metro South Health Services; Logan Hospital; Brisbane Queensland Australia 4113"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema N","family":"Quraishi","sequence":"additional","affiliation":[{"name":"SQ Therapy; 1 Harley street London UK W1G 9QD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"David","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry; De Crespigny Park PO Box 68 London UK SE5 8AF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sampson","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health University of Nottingham Innovation Park, Jubilee Campus Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health University of Nottingham Innovation Park, Jubilee Campus Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,10]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD001470.pub2-BIB0001|cit1","first-page":"305","article-title":"High dose neuroleptic treatment of chronic schizophrenic inpatients","volume":"8","author":"Cookson","year":"1983","journal-title":"Research Communications in Psychology, Psychiatry and Behaviour"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-198704000-00008","article-title":"The effects of a 50% reduction of cis(Z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime","volume":"2","author":"Cookson","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0004|cit3","first-page":"27","article-title":"Depot antipsychotics in schizophrenic patients: a comparison between haloperidol decanoate and flupenthixol decanoate","volume":"Suppl 1","author":"Eberhard","year":"1986","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0003|cit4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0447.1986.tb06242.x","article-title":"Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison","volume":"74","author":"Eberhard","year":"1986","journal-title":"Acta Psychiatria Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0005|cit5","first-page":"534","article-title":"Double-blind comparison of 2 depot neuroleptics (perphenazine enanthate and flupentixol decanoate) in chronic schizophrenia (author's transl)","volume":"50","author":"Eufe","year":"1979","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-0447.1975.tb00029.x","article-title":"Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia","volume":"52","author":"Gerlach","year":"1975","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0007|cit7","first-page":"69","article-title":"Double blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia","volume":"1","author":"Javed","year":"1991","journal-title":"Pakistan Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1192\/bjp.151.5.634","article-title":"Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia","volume":"151","author":"Johnson","year":"1987","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000468286","article-title":"Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia","volume":"12","author":"Kelly","year":"1977","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/08039489009096549","article-title":"Community-based rehabilitation of schizophrenia","volume":"44","author":"Lundin","year":"1990","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0011|cit11","first-page":"110","article-title":"The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients implications for community psychiatry","volume":"12","author":"Martyns-Yellowe","year":"1993","journal-title":"West African Journal of Medicine"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1192\/bjp.135.2.175","article-title":"High dose flupenthixol decanoate in chronic schizophrenia","volume":"135","author":"McCreadie","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0447.1979.tb00281.x","article-title":"A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia","volume":"60","author":"Pinto","year":"1979","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/030006058601400204","article-title":"A comparative trial of depot pipothiazine","volume":"14","author":"Steinert","year":"1986","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot withdrawal study. Palsma concentration of fluphenazine and flupenthixol and relapse frequency","volume":"78","author":"Wistedt","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00427950","article-title":"A depot neuroleptic withdrawal study neurological effects","volume":"80","author":"Wistedt","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0447.1983.tb09718.x","article-title":"Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology","volume":"67","author":"Wistedt","year":"1983","journal-title":"Acta Psychiatria Scandanavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0018|cit18","unstructured":"Arango C Oral or depot antipsychotics for people with schizophrenia and a history of violence Stanley Foundation Research Programs 1999"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1600-0447.1974.tb09710.x","article-title":"A study of flupenthixol decanoate and pipothiazine undecylenate in schizophrenics","volume":"50","author":"Astrup","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0447.1973.tb08446.x","article-title":"Clinical experience with DEPOT neuroleptics","volume":"246","author":"Bakke","year":"1973","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"4","key":"10.1002\/14651858.CD001470.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00583530","article-title":"Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic","volume":"18","author":"Barnes","year":"1983","journal-title":"Social Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0022|cit22","unstructured":"Benkert O M\u00fcller-Siecheneder F Wetzel H Negative and depressive symptoms in acute schizophrenic episodes- do they improve under neuroleptic treatment? 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK 1996 6356386 84045025"},{"issue":"Suppl.3","key":"10.1002\/14651858.CD001470.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S0924-977X(04)80350-X","article-title":"Antipsychotic treatment adherence and violence in schizophrenia outpatients: a randomized prospective trial","volume":"14","author":"Bombin","year":"2004","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/147323000102900601","article-title":"Clinical advantages of amisulpride in the treatment of acute schizophrenia","volume":"29","author":"Burns","year":"2001","journal-title":"Journal of International Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0029|cit25","first-page":"156","article-title":"ECT in Schizophrenia","volume":"44","author":"Chanpattana","year":"1999","journal-title":"Journal of the Psychiatric Association of Thailand"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0025|cit26","first-page":"558","article-title":"The use of the stabilization period in electroconvulsive therapy research in schizophrenia: II. Implementation","volume":"82","author":"Chanpattana","year":"1999","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0026|cit27","first-page":"558","article-title":"The use of the stabilization period in electroconvulsive therapy research in schizophrenia: II. Implementation","volume":"82","author":"Chanpattana","year":"1999","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0027|cit28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00124509-199909000-00002","article-title":"Continuation ECT in treatment resistant schizophrenia: a controlled study","volume":"15","author":"Chanpattana","year":"1999","journal-title":"Journal of ECT"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0028|cit29","unstructured":"Chanpattana W Sackeim HA Techakasem P Chakrabhand S ECT in schizophrenia 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA 1999 10211147 99227593"},{"issue":"2-3","key":"10.1002\/14651858.CD001470.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/j.1552-4604.1978.tb02436.x","article-title":"A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients","volume":"18","author":"Chouinard","year":"1978","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0010-440X(80)90090-5","article-title":"Depot fluphenazine and flupenthixol in the treatment of stabilized schizophrenics. A double-blind comparative trial","volume":"21","author":"Chowdhury","year":"1980","journal-title":"Comprehensive Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2007-1016982","article-title":"Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine","volume":"21","author":"Classen","year":"1988","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","article-title":"Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia","volume":"15","author":"Colonna","year":"2000","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001470.pub2-BIB0034|cit34","first-page":"S24","article-title":"Side effects during long-term treatment with depot antipsychotic medication","volume":"14","author":"Cookson","year":"1991","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"651P","DOI":"10.1111\/j.1365-2125.1977.tb00823.x","article-title":"Serum prolactin as an index of dopamine receptor blockade in acute schizophrenia","volume":"4","author":"Cotes","year":"1977","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001470.pub2-BIB0036|cit36","first-page":"269","article-title":"Fluphenazine and flupenthixol decanoate in psychiatric outpatients practice","volume":"23","author":"Coufal","year":"1981","journal-title":"Activa Nervosa Superior (Praha)"},{"issue":"5","key":"10.1002\/14651858.CD001470.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"648P","DOI":"10.1111\/j.1365-2125.1977.tb00820.x","article-title":"The clinical effects of the isomers of flupenthixol: the consequences of dopamine receptor blockade in acute schizophrenia (Proceedings)","volume":"4","author":"Crow","year":"1977","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0038|cit38","first-page":"466P","article-title":"Stereochemical specificity in the antipsychotic effects of flupenthixol in man (Proceedings)","volume":"59","author":"Crow","year":"1977","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.148.2.120","article-title":"A randomised controlled trial of prophylactic neuroleptic treatment","volume":"148","author":"Crow","year":"1986","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0040|cit40","first-page":"469","article-title":"Long-term depot maintenance of chronic schizophrenic out patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.146.5.464","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine- placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1192\/bjp.146.5.474","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.146.5.464","article-title":"Long term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the Medical Reseach Council fluphenazine\/placebo trial","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0920-9964(99)00147-4","article-title":"Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients","volume":"49","author":"Dahmen","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"July","key":"10.1002\/14651858.CD001470.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1600-0447.1980.tb00621.x","article-title":"Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics","volume":"62","author":"Deberdt","year":"1980","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0047|cit47","first-page":"7","article-title":"A double-blind trial of fluspirilene versus flupenthixol decanoate in the treatment of schizophrenic inpatients","volume":"15","author":"Demerdash","year":"1981","journal-title":"Journal of Kuwait Medical Association"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0049|cit48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0447.1980.tb07081.x","article-title":"Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. II Factor analysis of the CPRS sub-scale for schizophrenia","volume":"279","author":"Dencker","year":"1980","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0048|cit49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1980.tb07080.x","article-title":"Clopenthixol and \ufb02upenthixol depot preparations in outpatient schizophrenics","volume":"4","author":"Dencker","year":"1980","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.1980.tb07084.x","article-title":"Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study","volume":"279","author":"Dencker","year":"1980","journal-title":"Acta Psychiatrica Scandinavica, Supplementum"},{"issue":"1, 2","key":"10.1002\/14651858.CD001470.pub2-BIB0051|cit51","first-page":"225","article-title":"Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomised double-blind trial","volume":"49","author":"Dittmann","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0052|cit52","unstructured":"Dittmann RW Diehl A Hubrich P Maras A Gattaz WF Randomized double-blind trial: olanzapine vs flupenthixol 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004714-198706000-00011","article-title":"Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol","volume":"7","author":"Ehmann","year":"1987","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0054|cit54","unstructured":"Eli Lilly Company HGBL: olz v flupentixol Unpublished report 2001"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0055|cit55","first-page":"170","article-title":"Treatment of schizophrenia using depot neuroleptics","volume":"72","author":"Faltus","year":"1976","journal-title":"Ceskoslovenska Psychiatrie"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000468199","article-title":"The problem of post-psychotic schizophrenic depressions and pharmacological induction","volume":"10","author":"Floru","year":"1975","journal-title":"International Pharmacopsychiatria"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001470.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00004850-199705002-00004","article-title":"Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies","volume":"12","author":"Freeman","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S0033291700021607","article-title":"Skin conductance responsivity during acute episodes of schizophrenia as a predictor of symptomatic improvement","volume":"9","author":"Frith","year":"1979","journal-title":"Psychological Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/s-2004-832684","article-title":"Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial","volume":"37","author":"Gattaz","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"42","key":"10.1002\/14651858.CD001470.pub2-BIB0060|cit60","first-page":"30","article-title":"Flupentixol ist Risperidon ebenburtig","volume":"146","author":"Genstahler","year":"2001","journal-title":"Pharmazeutische Zeitung"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0061|cit61","first-page":"7","article-title":"Clinical profiles of action, individual treatment preferences, affects and contraindications of three depot neuroleptics compared in a multicentre trial","volume":"25","author":"Giannelli","year":"1990","journal-title":"Rivista di Psichiatria"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001470.pub2-BIB0062|cit62","first-page":"S120","article-title":"Flupenthixol and risperidone: equivalent efficacy against negative symptoms in schizophrenia","volume":"5","author":"Glaser","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001470.pub2-BIB0063|cit63","first-page":"S120","article-title":"Subjective experiences and satisfaction of schizophrenic patients treated with flupenthixol or risperidone: results of a double-blind trial","volume":"5","author":"Glaser","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0064|cit64","first-page":"344","article-title":"Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group","volume":"25","author":"Glick","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0065|cit65","unstructured":"Godleski LS Goldsmith LJ Zettwoch NC Stikovac DC Lewis SJ Depot antipsychotic versus oral olanzapine treatment 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4088\/JCP.v64n0203","article-title":"Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia","volume":"64","author":"Godleski","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/08039486709094625","article-title":"Clinical experiences with flupenthixol in psychiatric patients","volume":"21","author":"Gottfries","year":"1967","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0068|cit68","first-page":"53","article-title":"A double-blind investigation with flupenthixol and trifluoperazine at treatment of schizophrenic psychoses","volume":"217","author":"Gottfries","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"5","key":"10.1002\/14651858.CD001470.pub2-BIB0069|cit69","first-page":"507","article-title":"Flupenthixol and flupenthixol decanoate with special reference to their antipsychotic effect","volume":"74","author":"Gottfries","year":"1974","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1192\/bjp.119.552.547","article-title":"Flupenthixol and trifluoperazine: a double-blind investigation in the treatment of schizophrenics","volume":"119","author":"Gottfries","year":"1971","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.1974.tb08890.x","article-title":"Flupenthixol decanoate in treatment of out-patients","volume":"Suppl 255","author":"Gottfries","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0006-3223(98)00125-5","article-title":"Neuroendocrine response to antipsychotics: effects of drug type and gender","volume":"45","author":"Grunder","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00496067","article-title":"A comparative trial of the decanoates of flupenthixol and fluphenazine","volume":"64","author":"Hamilton","year":"1979","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1600-0447.1975.tb00217.x","article-title":"A comparative trial of fluphenazine decanoate and flupenthixol decanoate","volume":"51","author":"Haslam","year":"1975","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD001470.pub2-BIB0075|cit75","first-page":"151","article-title":"Influence of psychopathological symptoms on subjective quality of life of schizophrenic patients","volume":"10","author":"Hertling","year":"2003","journal-title":"Psychopharmakotherapie"},{"issue":"3S","key":"10.1002\/14651858.CD001470.pub2-BIB0076|cit76","first-page":"31s","article-title":"Amisulpride vs flupentixol in the treatment of schizophrenia with predominant positive symptomatology: a controlled double-blind study","volume":"10","author":"Hillert","year":"1994","journal-title":"Neuropyschopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0077|cit77","first-page":"62","article-title":"Intermittent medication as an alternative to maintenance medication in the treatment of schizophrenia: a preliminary report","volume-title":"Bewaltigung der Schizophrenie","author":"Hirsch","year":"1986"},{"issue":"5","key":"10.1002\/14651858.CD001470.pub2-BIB0078|cit78","first-page":"269","article-title":"A study on therapeutic efficacy of flupenthixol in treating chronic schizophrenics of type II","volume":"28","author":"Huang","year":"1995","journal-title":"Chinese Journal of Neurology and Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001470.pub2-BIB0079|cit79","first-page":"739","article-title":"Clinical evaluation on effect of flupentixol, a neuroleptic drug, on schizophrenia by double-blind controlled trial","volume":"13","author":"Ishimaru","year":"1971","journal-title":"Seishin Igaku (Clinical Psychiatry)"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0447.1975.tb11092.x","article-title":"A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia","volume":"51","author":"Johnson","year":"1975","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"8069","key":"10.1002\/14651858.CD001470.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(78)90193-9","article-title":"Mechanism of the antipsychotic effect in the treatment of acute schizophrenia","volume":"1","author":"Johnstone","year":"1978","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1192\/bjp.134.1.28","article-title":"The outcome of severe acute schizophrenic illnesses after one year","volume":"134","author":"Johnstone","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0447.1980.tb07082.x","article-title":"Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels","volume":"61","author":"Jorgensen","year":"1980","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF00436100","article-title":"Serum concentrations of cis(Z)-flupenthixol and prolactin in chronic schizophrenic patients treated with flupenthixol and cis(Z)-flupenthixol decanoate","volume":"77","author":"Jorgensen","year":"1982","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00427342","article-title":"3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol","volume":"64","author":"Joseph","year":"1979","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0086|cit86","first-page":"19","article-title":"Flupentixol vs fluphenazine in schizophrenia patients: a randomized controlled trial","volume":"15","author":"Ju","year":"1996","journal-title":"New Drugs and Clinical Remedies"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD001470.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?","volume":"16","author":"Kelemen","year":"2006","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0088|cit88","unstructured":"King KG Dittmann RW Diehl A Hubrich P Maras A Gattaz WF Randomized double-blind trial: olanzapine vs flupenthixol 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF02316862","article-title":"Perphenazine decanoate and cis(z)-flupenthixol decanoate in maintenance treatment of schizophrenic outpatients","volume":"105","author":"Kistrup","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1192\/bjp.135.6.515","article-title":"Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients","volume":"135","author":"Knights","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0091|cit91","first-page":"371","article-title":"An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia","volume":"5","author":"Kong","year":"1989","journal-title":"Pharmatherapeutica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000407841","article-title":"AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics","volume":"20","author":"Lapierre","year":"1983","journal-title":"Modern Problems of Pharmacopsychiatry"},{"issue":"775","key":"10.1002\/14651858.CD001470.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/bmj.3.5775.599","article-title":"Trial of maintenance therapy in schizophrenia","volume":"3","author":"Leff","year":"1971","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0094|cit94","first-page":"266","article-title":"Two year follow up observations on treatments of type schizophrenia with maintenance dose of clozapine or fluanxol","volume":"12","author":"Liu","year":"1999","journal-title":"Acta Medicinae Sinica"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0095|cit95","first-page":"117","article-title":"A comparative study of fluanxol and chlorpromazine used for schizophrenia","volume":"21","author":"Liu","year":"2000","journal-title":"Journal of Taishan Medical College"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0096|cit96","unstructured":"Macmillan JF The first schizophrenic illness - presentation and short term outcome, incorporating a trial of prophylactic neuroleptic maintenance therapy versus placebo PhD dissertation submitted to the University of Edinburgh 1984 112 40"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1192\/bjp.148.2.128","article-title":"Short-term outcome in trial entrants and trial eligible patients","volume":"148","author":"MacMillan","year":"1986","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0447.1989.tb03032.x","article-title":"The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group","volume":"80","author":"McCreadie","year":"1989","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1192\/bjp.152.4.470","article-title":"The Scottish First Episode Schizophrenia Study V. One-year follow-up. The Scottish Schizophrenia Research Group","volume":"152","author":"Scottish Schizophrenia Research Group","year":"1988","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1192\/bjp.150.3.334","article-title":"The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol","volume":"150","author":"Scottish Schizophrenia Research Group","year":"1987","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1192\/bjp.161.4.496","article-title":"The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings. The Scottish Schizophrenia Research Group","volume":"161","author":"Scottish Schizophrenia Research Group","year":"1992","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1192\/bjp.150.3.338","article-title":"The Scottish First Episode Schizophrenia Study. III. Cognitive performance","volume":"150","author":"The Scottish Schizophrenia Research Group","year":"1987","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001470.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/S0924-977X(97)88747-0","article-title":"Depressive symptoms in acute schizophrenia: evaluation and outcome under new antipsychotics","volume":"7","author":"Mueller MJ","year":"1997","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001470.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00004850-200209000-00005","article-title":"Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: An evaluation using confirmatory factor analysis","volume":"17","author":"Mueller","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0105|cit105","unstructured":"Muller MJ Benkert O Depressive symptoms in acute schizophrenia: evaluation and outcome under new antipsychotics 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997 1487623 93139483"},{"issue":"1,2","key":"10.1002\/14651858.CD001470.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0920-9964(97)88704-X","article-title":"Differential treatment effects of amisulpride versus flupentixol on latent dimensions of depressive and negative symptoms in acute schizophrenia","volume":"29","author":"Muller","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0107|cit107","unstructured":"M\u00fcller MJ Wetzel H Benkert O Depressive symptoms in acute psychotic disorders: evaluation methods and treatment strategies 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998 2690890 90104929"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"M\u00fcller MJ Wetzel H Benkert O Latent dimensions of depressive and negative symptoms in acute schizophrenia: treatment effects of high dose amisulpride vs. flupentixol 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80355-6"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1192\/bjp.139.1.16","article-title":"Platelet monoamine oxidase activity in acute schizophrenia: relationship to symptomatology and neuroleptic medication","volume":"139","author":"Owen","year":"1981","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001470.pub2-BIB0110|cit110","first-page":"A74","article-title":"73% medication compliance needed to achieve therapeutic benefit in first episode psychosis (FEP)","volume":"39","author":"O\u2019Regan","year":"2005","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0111|cit111","unstructured":"Pach J Finkbeiner T Wolstein J Glaser T Maintenance therapy with flupenthixol-decanoate in chronic schizophrenics: a one-year follow-up study XXIst C.I.N.P. Congress. Glasgow, Scotland, UK"},{"issue":"5","key":"10.1002\/14651858.CD001470.pub2-BIB0112|cit112","first-page":"354","article-title":"Flupenthixol versus haloperidol in acute psychosis","volume":"3","author":"Parent","year":"1983","journal-title":"Pharmatherapeutica"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0113|cit113","first-page":"617","article-title":"Flupenthixol versus haloperidol in acute psychotic episodes","volume":"82","author":"Parent","year":"1982","journal-title":"Acta Psychiatrica Belgica"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001470.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1055\/s-2003-39746","article-title":"Comparative effectiveness of flupenthixol and risperidone on negative symptoms","volume":"30","author":"Philipp","year":"2003","journal-title":"Psychiatrische Praxis"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-006-0611-0","article-title":"Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol","volume":"190","author":"Reimold","year":"2007","journal-title":"Psychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001470.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/S0924-977X(98)80392-1","article-title":"Amisulpride improves affective symptoms in acute schizophrenia","volume":"8","author":"Rein","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0117|cit117","unstructured":"Rein W Turjanski S Fleurot O Amisulpride in the treatment of productive schizophrenia 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain 1996"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0118|cit118","first-page":"259","article-title":"Problems posed by trial use of prolonged action neuroleptics in acute psychiatric syndromes","volume":"1","author":"Ropert","year":"1973","journal-title":"Annales Medico-Psychologiques"},{"issue":"5","key":"10.1002\/14651858.CD001470.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.pnpbp.2007.02.014","article-title":"Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms","volume":"31","author":"Ruhrmann","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000063574","article-title":"Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels","volume":"46","author":"Schlosser","year":"2002","journal-title":"Neuropsychobiology"},{"issue":"7","key":"10.1002\/14651858.CD001470.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archpsyc.1978.01770310099008","article-title":"Standard and long-acting depot neuroleptics in chronic schizophrenics: an 18-month open multicentric study","volume":"35","author":"Simon","year":"1978","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/030006058401200103","article-title":"Therapeutic efficacy of flupenthixol decanoate in schizoaffective disorder: a clinical evaluation","volume":"12","author":"Singh","year":"1984","journal-title":"Journal of International Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00491981","article-title":"Comparison of serum levels after intramuscular injections of 2% and 10% cis(z)-flupenthixol decanoate in viscoleo to schizophrenic patients","volume":"65","author":"Stauning","year":"1979","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD001470.pub2-BIB0124|cit124","first-page":"1492","article-title":"Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication","volume":"28","author":"Steuber","year":"1978","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S1461145706006651","article-title":"Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication","volume":"10","author":"Strous","year":"2007","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/bjp.124.1.058","article-title":"Flupenthixol decanoate in schizophrenia","volume":"124","author":"Trueman","year":"1974","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/08039489409078159","article-title":"A 3-year study of maintenance therapy with depot neuroleptics","volume":"48","author":"Tuninger","year":"1994","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1192\/bjp.169.5.618","article-title":"Large variations of plasma levels during maintenance treatment with depot neuroleptics","volume":"169","author":"Tuninger","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1192\/bjp.146.4.439","article-title":"Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics","volume":"146","author":"Turbott","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0130|cit130","first-page":"327","article-title":"Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome","volume":"21","author":"Turbott","year":"1987","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF00180839","article-title":"A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients","volume":"88","author":"Vaddadi","year":"1986","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0132|cit132","first-page":"313","article-title":"Flupentixol in psychoses. Controlled clinical trial","volume":"10","author":"Vinar","year":"1968","journal-title":"Activitas Nervosa Superior"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0133|cit133","first-page":"176","article-title":"Schizophrenic syndromes improving without neuroleptic drug treatment","volume":"72","author":"Vinar","year":"1976","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0134|cit134","first-page":"269","article-title":"Stabilization and DEPOT neuroleptic dosages","volume":"29","author":"Weiden","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"10","key":"10.1002\/14651858.CD001470.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1176\/ps.46.10.1049","article-title":"Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen","volume":"46","author":"Weiden","year":"1995","journal-title":"Psychiatric Services"},{"issue":"1,2","key":"10.1002\/14651858.CD001470.pub2-BIB0136|cit136","first-page":"278","article-title":"A comparison of atypical and DEPOT antipsychotic drugs in preventing jail recidivism among outpatients with schizophrenia","volume":"49","author":"Weisman","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0137|cit137","first-page":"227","article-title":"High-dose amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology","volume":"28","author":"Wetzel","year":"1995","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001470.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002130050614","article-title":"Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology: a double blind controlled study comparing a selective D2 like antagonist to a mixed D1 \/D2 like antagonist. The Amisulpride Study Group","volume":"137","author":"Wetzel","year":"1998","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0140|cit139","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1981.tb00761.x","article-title":"A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients","volume":"64","author":"Wistedt","year":"1981","journal-title":"Acta Psychiatrica Scandanavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0139|cit140","first-page":"369","article-title":"Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics","volume":"44","author":"Wistedt","year":"1983","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/08039489509099719","article-title":"How does the psychiatric patient feel about depot treatment, compulsion or help?","volume":"Suppl 35","author":"Wistedt","year":"1995","journal-title":"Nordic Journal of Psychiatry"},{"issue":"15","key":"10.1002\/14651858.CD001470.pub2-BIB0142|cit142","first-page":"1263","article-title":"[San fu zuo dun yu lv bing zuo zhi liao jing shen fen lie zheng de guan cha hu li]","volume":"11","author":"Yin","year":"2005","journal-title":"Heilongjiang Nursing Journal [Modern Nursing]"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001470.pub2-BIB0143|cit143","first-page":"S16","article-title":"Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate","volume":"14","author":"Youssef","year":"1991","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0144|cit144","unstructured":"Aaes-Jorgenson A Pharmacokinetics of oral and depot neuroleptics - clinical relevance Symposium Espo"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0447.1978.tb02357.x","article-title":"A comprehensive psychopathological rating scale","volume":"Suppl 271","author":"Asberg","year":"1978","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/978-3-642-93700-2_5","article-title":"Effect of Flupenthixol on Negative symptoms and Depresive syndromes in Schizophrenic patients","volume-title":"Flupentixol. Typisches oder Atypisches Wirkspektrum?","author":"Bandelow","year":"1998"},{"issue":"6","key":"10.1002\/14651858.CD001470.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/00002018-199410060-00005","article-title":"Long term depot antipsychotics. A risk benefit assessment","volume":"10","author":"Barnes","year":"1994","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD001470.pub2-BIB0151|cit151","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1192\/bjp.129.5.476","article-title":"Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia","volume":"129","author":"Carney","year":"1976","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0154|cit154","first-page":"233","article-title":"Extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Science"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0155|cit155","volume-title":"The Neuropsychology of Schizophrenia","author":"David","year":"1994"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0156|cit156","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data In: Abstracts of 8th International Cochrane Colloquium"},{"issue":"Suppl 279","key":"10.1002\/14651858.CD001470.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.1980.tb07084.x","article-title":"Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study","volume":"61","author":"Dencker","year":"1980","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0159|cit159","volume-title":"Burdens of disease: a discussion document","author":"Department of Health","year":"1996"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0162|cit162","first-page":"140-9. [PubMed:","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31(1)","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4613-4042-3_3","article-title":"Behavioural actions of neuroleptics","volume-title":"Handbook of Psychopharmacology","volume":"10","author":"Fielding","year":"1978"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0165|cit165","unstructured":"Glaser T Sommermeyer M Fassbinder M Mauler F Receptor binding of flupenthixol and other neuroleptics PT06004, XXIst CINP Congress, Glasgow 1998 6 21"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0167|cit167","first-page":"124","article-title":"ECDEU Assessment manual for psychopharmacology. DHEW publication No (ADM)","volume-title":"DHEW Publication No. ADM 76\u2013338, US Government Printing Office, Washington, DC, USA, 1976.","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale of depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0169|cit169","first-page":"11","article-title":"Excess mortality of mental disorder","volume":"173(7)","author":"Harris","year":"July 1998","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0170|cit170","volume-title":"Compliance in Health Care","author":"Haynes","year":"1979"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0173|cit173","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD001470.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.1.5854.633","article-title":"Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial","volume":"1","author":"Hirsch","year":"1973","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0175|cit175","first-page":"799","article-title":"NOSIE-30: A treatment sensitive ward behavior scale","volume":"10","author":"Honigfeld","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0264180100000904","article-title":"Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten-country study","volume":"20","author":"Jablensky","year":"1992","journal-title":"Psychological Medicine Monograph Supplement"},{"issue":"2-3","key":"10.1002\/14651858.CD001470.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1600-0773.1971.tb00595.x","article-title":"Metabolism, distribution and excretion of flupenthixol decanoate in dogs and rats","volume":"29","author":"Jorgensen","year":"1971","journal-title":"Acta Pharmacologica et Toxicologica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/0024-3205(78)90580-5","article-title":"A sensitive and specific radioimmunoassay for cis(Z)- flupenthixol in human serum","volume":"23","author":"Jorgensen","year":"1978a","journal-title":"Life Science"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD001470.pub2-BIB0179|cit179","first-page":"30","article-title":"Depot neuroleptics: a comparison review of standard, intermediate and low-dose regimens","volume":"47","author":"Kane","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia","volume":"8","author":"Kane","year":"1998","journal-title":"European Neuropschopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0181|cit181","article-title":"Antidepressant effects of thioxanthenes","volume-title":"The Thioxanthenes, Basel, Karger","author":"Kato","year":"1969"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0182|cit182","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"1","key":"10.1002\/14651858.CD001470.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"42\u201354","DOI":"10.1034\/j.1600-0447.2002._10310.x","article-title":"Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European PsychiatricServices: Inputs Linked to Outcome Domains and Needs","volume":"105","author":"Knapp","year":"2002","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0447.1977.tb00174.x","article-title":"A standardised psychiatric assessment scale for rating chronic psychotic patients","volume":"55","author":"Krawiecka","year":"1977","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001470.pub2-BIB0187|cit187","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub2","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD001470.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0189|cit189","first-page":"23\u201341","article-title":"Cost of schizophrenia in England","volume":"10","author":"Mangalore","year":"2007","journal-title":"Journal of Mental Health Policy and Economics"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0190|cit190","unstructured":"Marshall M Personal communication 1998. Personal communication"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0191|cit191","first-page":"337","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"39","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD001470.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"9859","key":"10.1002\/14651858.CD001470.pub2-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0195|cit195","unstructured":"Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care NICE Guideline:CGS 82 Schizophrenia (update)"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0197|cit197","volume-title":"Insanity: A study of Major Psychiatric Disorders","author":"Priest","year":"1977"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0198|cit198","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00432123","article-title":"Steady-state serum concentrations after cis(Z)-flupentixol decanoate in Viscoleo(R)","volume":"80","author":"Saikia","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1470\u20131","DOI":"10.1136\/bmj.324.7352.1470","article-title":"Iatrogenic stigma of mental illness","volume":"324","author":"Sartorius","year":"2002","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1994.03520020051014","article-title":"Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynaecology journals","volume":"272","author":"Schulz","year":"1994","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001470.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0204|cit204","volume-title":"Shunned: Discrimination Against People with Mental Illness","author":"Thornicroft","year":"2006"},{"key":"10.1002\/14651858.CD001470.pub2-BIB0205|cit205","first-page":"3","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3(5)","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD001470.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD001470.pub2-BIB0207|cit207","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001470","article-title":"Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders","author":"David","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001470.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T08:58:38Z","timestamp":1746262718000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001470.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,10]]},"references-count":207,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001470.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,10]]}}}